Intravenous tenecteplase before endovascular thrombectomy in patients with acute basilar artery occlusion within 4.5–24 hours: study protocol and rationale
Open Access
- 7 April 2026
- journal article
- Published by BMJ in Stroke and Vascular Neurology
Abstract
Background and purpose: One clinical trial demonstrated the beneficial effect of intravenous tenecteplase for large vessel occlusion patients not undergoing endovascular thrombectomy (EVT) within 4.5–24 hours. However, for those with acute basilar artery occlusion (BAO) presenting beyond the 4.5-hour therapeutic window, it remains unknown whether intravenous thrombolysis before EVT is beneficial. This study hypothesised that treatment of acute BAO patients with intravenous tenecteplase before EVT will result in better clinical outcomes vs EVT alone within 4.5–24 hours. Methods and design: ATTENTION LATE is a prospective, multicentre, randomised, controlled, open-label trial with blinded endpoint assessment. This study will enrol patients with acute BAO who present within 4.5–24 hours of symptom onset. These patients will be randomised 1:1 to either intravenous tenecteplase bridging to EVT or EVT alone. Study outcomes: A score of 0–2 on the modified Rankin Scale at 90 days will serve as the primary endpoint. Discussion: The ATTENTION LATE trial evaluates whether administering intravenous tenecteplase is safe and effective for acute BAO patients prior to EVT beyond the 4.5-hour time frame. This trial could establish the basis for expanding the eligible patient population to receive intravenous thrombolysis and extending the time window for acute BAO. Trial registration number: NCT05701956 .Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (YD9110002014)
This publication has 27 references indexed in Scilit:
- Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysisThe Lancet, 2024
- Endovascular vs Medical Management of Acute Basilar Artery OcclusionJAMA Neurology, 2024
- Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trialThe Lancet Neurology, 2024
- Endovascular thrombectomy with versus without intravenous thrombolysis in patients with acute basilar artery occlusion: a systematic review and meta-analysisJournal of Neurology, 2024
- Time to Treatment With Intravenous Thrombolysis Before Thrombectomy and Functional Outcomes in Acute Ischemic StrokeJAMA, 2024
- Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trialsThe Lancet, 2023
- Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trialThe Lancet, 2022
- Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective RegistryJAMA Neurology, 2020
- A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic StrokeNew England Journal of Medicine, 2012
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007